Elan Corporation

Pharmaceutical company

About Us

Products

Elan Drug Technologies

Research & Development

News

Investor Relations

Careers

Governance

• • United States
    • Azactam®
    • Maxipime®
    • PRIALT®
    • TYSABRI® Information Center
• US Medical Information
• European Union

TYSABRI® INFORMATION CENTER

 

Recent News Form 6-K (12/15/08) Form 6-K (10/30/08 Form 6-K (7/31/2008) Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI® for the Treatment of Multiple Sclerosis (7/22/08) Data Presented at the 60th Annual Meeting of the American Academy of Neurology Offers Additional Support for Plasma Exchange as a Potential Tool to Accelerate TYSABRI® Removal (4/16/08)

Resources » Tysabri.com » National MS Society on Tysabri » FDA Infopage on TYSABRI

Biogen Idec and Elan Present New TYSABRI® Data at the 60th Annual Meeting of the American Academy of Neurology (4/15/08) FDA Approves TYSABRI® for the Treatment of Moderate-to-Severe Crohn's Disease (1/14/08) Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI® in Patients with Multiple Sclerosis (1/7/08) 2007 News Archive 2006 News Archive 2005 News Archive

TYSABRI is a registered trademark of Elan Pharmaceuticals, Inc. in the United States and of Elan Pharma International Ltd. in various countries outside the United States.

Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use